🏛️ Polity & GovernanceMAINS · GS2.13

Pregabalin moved to stricter Schedule H1

The pain drug Pregabalin is reclassified from Schedule H to the stricter Schedule H1 of the Drugs and Cosmetics Rules, 1945, to curb growing misuse.

What happened

The Union Ministry of Health and Family Welfare notified the inclusion of the drug Pregabalin under Schedule H1 of the Drugs Rules, 1945.
The change was made through Gazette Notification G.S.R. 377(E), dated 13 May 2026, published in the Gazette of India (Extraordinary) on 20 May 2026.
Pregabalin moves up one rung — from the ordinary prescription-drug Schedule H to the tighter Schedule H1 — without becoming a narcotic.
The trigger was reports from several States of misuse and abuse of Pregabalin, particularly among youth, alongside seizures of illegally stocked supplies.
Prescribed legitimately for chronic pain, neuropathies, fibromyalgia and certain neurological conditions, the drug has been diverted for its sedative, euphoric and dissociative effects.
Schedule H1 status now imposes a stricter sale, record-keeping and labelling discipline, with penal consequences for breach under the Drugs and Cosmetics Act, 1940.

Background & context

India regulates the manufacture, sale and distribution of medicines through the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 made under it. The Act is the parent law; the Rules are the operating detail. Within the Rules sit a series of "Schedules" — lettered lists that group drugs and set the conditions attached to each group. Schedule H is the large list of prescription-only medicines that may be sold only against a registered medical practitioner's prescription. Schedule X covers the most tightly controlled habit-forming substances, requiring special licences and the keeping of stock and sale records for a fixed period. Schedule H1 was carved out in 2013 as an intermediate, stricter sub-class within the prescription regime — created precisely to slow the over-the-counter availability of a watch-list of antibiotics, anti-TB drugs and habit-forming sedatives whose unmonitored sale was driving antimicrobial resistance and substance abuse.

The administering chain runs from the Ministry of Health and Family Welfare at the top, through the Central Drugs Standard Control Organisation (CDSCO) headed by the Drugs Controller General of India (DCGI), down to State Drug Controllers who licence and inspect retail chemists on the ground. A change of Schedule is therefore a regulatory act, not a fresh law: the Ministry amends the Rules by gazette notification — here G.S.R. 377(E) — and the obligation immediately binds manufacturers, wholesalers and retail pharmacists. Pregabalin's reclassification is the latest addition to the H1 watch-list, reflecting a pattern where a medicine begins as a routine prescription item and is escalated once field evidence of diversion accumulates.

Pregabalin itself is a gabapentinoid — a molecule that calms over-active nerve signalling. That same calming action, taken in excess or combined with opioids and alcohol, produces the intoxicating "high" that has made it a drug of abuse in several countries and, increasingly, in pockets of India. The notification is the State's measured response: rather than banning a clinically useful medicine or routing it through the heavier narcotics machinery, it tightens the prescription and audit trail so that legitimate patients keep access while casual diversion becomes harder.

The regulatory chain (who does what)

Understanding the change means tracing the chain it travels through. Parliament enacted the Drugs and Cosmetics Act, 1940, which delegates rule-making to the Central Government. The Ministry of Health and Family Welfare exercises that delegated power to frame and amend the Drugs and Cosmetics Rules, 1945 — and it is this Ministry that issued G.S.R. 377(E) to add Pregabalin to Schedule H1. Technical advice on whether a drug warrants tighter scheduling flows from the Drugs Technical Advisory Board (DTAB), the statutory expert body that advises the Centre on technical drug matters, and from the Central Drugs Standard Control Organisation (CDSCO), the national regulator headed by the Drugs Controller General of India (DCGI). CDSCO sets standards and approves new drugs; the actual licensing of chemists and the day-to-day inspection of pharmacies, however, is done by State Drug Controllers, because the sale and distribution of drugs is licensed at the State level. So the sequence here is: who advises (DTAB/CDSCO) → who notifies (the Ministry, by gazette) → who enforces on the ground (State Drug Controllers and Drug Inspectors). For Prelims this "who approves vs who notifies vs who enforces" distinction is exactly the kind of separation a statement-based question probes.

How H1 compares to its peers

Set against its nearest neighbour, Schedule H1 is best understood as Schedule H "plus two extra obligations": the separate sale register and the boxed warning label. Against Schedule X — the heaviest tier inside the Drugs and Cosmetics framework — H1 is lighter: X demands a special licence to even stock the drug and prescriptions to be retained for two years, whereas an H1 drug can be stocked by an ordinary licensed chemist who simply maintains the dedicated register. And against the entirely separate NDPS Act, 1985, H1 is far lighter still: NDPS criminalises possession and trafficking of narcotic and psychotropic substances with stringent penalties and a reverse burden of proof, while an H1 listing keeps the medicine in the ordinary pharmacy system and merely audits its sale. Globally, Pregabalin has been reclassified as a controlled substance in jurisdictions such as the United Kingdom, where it was moved to Class C in 2019 — so India's H1 step mirrors a wider international trend of tightening gabapentinoid controls, while choosing a lighter-touch instrument than outright scheduling under a narcotics law.

For Prelims

What changed: Pregabalin moved from Schedule H to Schedule H1 of the Drugs and Cosmetics Rules, 1945.
Instrument: Gazette Notification G.S.R. 377(E), dated 13 May 2026; published in the Gazette of India Extraordinary on 20 May 2026.
Notifying authority: Union Ministry of Health and Family Welfare (drug regulation under CDSCO / DCGI, enforced by State Drug Controllers).
Parent framework: Drugs and Cosmetics Act, 1940 (the Act) read with the Drugs and Cosmetics Rules, 1945 (the Rules); Schedule H1 introduced in 2013.
H1 sale rule: sale only against a valid prescription from a Registered Medical Practitioner (RMP).
H1 record rule: the retailer must maintain a separate register of prescriptions and sales (name of prescriber, patient, drug, quantity, date), retained for the prescribed period.
H1 label rule: the package must carry the mandatory "Schedule H1 Drug Warning" printed within a box, advising that the drug be sold only on the prescription of an RMP and not be used without medical advice.
Clinical use of Pregabalin: chronic pain, peripheral and central neuropathies, fibromyalgia, and certain neurological conditions; a gabapentinoid.
Why misused: sedative, euphoric and dissociative effects, especially when combined with opioids or alcohol.
Penalty: non-compliance attracts penal action under the Drugs and Cosmetics Act, 1940 and Rules.

For UPSC: Schedule H1 = prescription-only + separate sale register + boxed "Schedule H1 Drug Warning" label. It sits above Schedule H but below Schedule X under the Drugs and Cosmetics Rules, 1945 — and it is not the NDPS/narcotics regime.

What it is NOT: Schedule H1 is not the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 — Pregabalin has not been declared a narcotic or psychotropic substance. It is not Schedule X (which needs a special licence and is the most tightly controlled habit-forming class). It is not a ban — the medicine remains lawfully available to genuine patients on prescription. And the reclassification is done by amending the Rules via gazette notification, not by passing a new Act of Parliament.

The Schedule set (carry the full comparison)

Schedule H: the broad list of prescription-only drugs; sale only on an RMP's prescription.
Schedule H1: a stricter sub-set of Schedule H (created 2013) — adds a separate sale register and a mandatory boxed warning label; covers select antibiotics, anti-TB drugs and habit-forming sedatives. Pregabalin now sits here.
Schedule X: the most tightly controlled habit-forming substances; needs a special licence to stock/sell and mandatory record-keeping (e.g., barbiturates and certain narcotics regulated under the Rules).
Schedule G: drugs to be used only under medical supervision, carrying a "caution" label (e.g., certain hormones, anti-diabetics).
Distinct regime — NDPS Act, 1985: governs narcotic drugs and psychotropic substances separately from the Drugs and Cosmetics framework; Pregabalin is not placed here.

A typical Prelims trap pairs the wrong Schedule with the wrong control. The defining "yes/no" properties to hold are: H = prescription only; H1 = prescription + separate register + warning label; X = special licence + record-keeping; NDPS = a separate Act entirely. Knowing the ordering — H < H1 < X in strictness, with NDPS as a parallel and heavier track — survives both the "match the pairs" and the "how many statements are correct" formats.

Why it matters

The reclassification addresses a recurring governance problem: a clinically valuable medicine becoming a cheap, legal-looking intoxicant when it slips out of the prescription channel. Banning the drug would punish genuine pain and neuropathy patients; routing it through the narcotics machinery would be disproportionate and would strain an already stretched enforcement system. Schedule H1 is the calibrated middle path — it preserves therapeutic access while building an audit trail (the separate register) that lets State Drug Controllers trace abnormal sales back to a chemist or prescriber. The boxed warning label also nudges the patient and the dispenser at the point of sale.

It illustrates how India's drug regulator escalates control in stages as field evidence accumulates, and how a subordinate-legislation tool (amending Rules by notification) lets the executive respond quickly to an emerging public-health threat without waiting for fresh primary legislation. The move also sits at the intersection of youth substance abuse, pharmacy regulation and antimicrobial-style watch-listing — the same H1 mechanism that was first deployed to slow antibiotic over-the-counter sales is here repurposed against sedative diversion.

For Mains

Data

A concrete, datable 2026 example of executive regulation tightening drug control — Pregabalin moved to Schedule H1 by G.S.R. 377(E) — usable to substantiate answers on health governance and the regulation of medicines.

Exemplification

Illustrates the graded-control model of the Drugs and Cosmetics Rules (H → H1 → X) and how the State balances access to essential medicines against the risk of diversion and substance abuse among the youth.

Problematisation

The notification itself admits the gap it responds to: misuse and illegal stocking despite an existing prescription regime — pointing to weak last-mile pharmacy enforcement that a register alone may not fully close.

Way-forward

Supports arguments for digitised, interlinked sale registers, prescription audits and pharmacist accountability as the next step beyond a paper H1 register.

Deploys into: health-sector governance and regulation of medicines (GS2.13); the use of subordinate legislation and watch-listing to manage emerging public-health risks; youth substance abuse and the access-versus-control trade-off in pharmaceutical policy.

Ministry of Health and Family Welfare · 2026-05-22 · PRID 2263975 · PIB source ↗